logo

For the Inventor, By the Inventor

Labuan, Malaysia

Biolitec Pharma Marketing Ltd

USPTO Granted Patents = 39

% Expired Patents = 33.3



Trademarks = 6

Forward Citations = 130

Loading Chart...
Loading Chart...

51 inventors (with patents filed for the assignee):

goldMedal Wolfgang Neuberger (24 out of 111 patents)

silverMedal Volker Albrecht (12 out of 21 patents)

bronzeMedal Susanna Gräfe (8 out of 9 patents)

4.  Arno Wiehe (6 out of 14 patents)

5.  Burkhard Gitter (5 out of 10 patents)

6.  Walter Cecchetti (5 out of 10 patents)

7.  Dietrich Scheglmann (4 out of 5 patents)

8.  Nikolay Nifantiev (3 out of 12 patents)

9.  Gerhard Wieland (3 out of 5 patents)

10.  Daniel Aicher (3 out of 3 patents)

11.  Christian B W Stark (3 out of 3 patents)

12.  Danilo Castro (3 out of 4 patents)

13.  Fabio Coluccia (2 out of 3 patents)

14.  Stefan Spaniol (2 out of 8 patents)

15.  Alfred Fahr (2 out of 3 patents)


Core Competencies:
Anti-Microbial PDT
Laser Treatment Devices
Nanoparticle Carriers
Pegylated Compounds
Endoluminal Laser Ablation
Cosmetic Laser Treatment
Vascular Treatment Methods
Photosensitizer Formulations
Diode Laser Systems
Medical Laser Procedures
Transdermal Treatment
Vein Treatment Devices

39 patents:

1. 9411113 - Fiber optic connector for laser sources (2016-08-09),
2. 9409037 - Enhanced anti-microbial PDT (2016-08-09),
3. 9315510 - [object Object] (2016-04-19),
4. 9308185 - Glyco-substituted dihydroxy-chlorins and β-functionalized chlorins for anti-microbial photodynamic therapy (2016-04-12),
5. 9216166 - Anti-microbial photodynamic therapy (2015-12-22),
6. 9211283 - Nanoparticle carrier systems based on human serum albumin for photodynamic therapy (2015-12-15),
7. 9156849 - Application of β-functionalized dihydroxy-chlorins for PDT (2015-10-13),
8. 9149335 - Contact free and perforation safe endoluminal laser treatment device and method (2015-10-06),
9. 9149333 - Endoluminal laser ablation device and improved method for treating veins (2015-10-06),
10. 9040079 - Pegylated compounds for age-related macular degeneration (2015-05-26),
11. 9034024 - Method for treatment of varicocele (2015-05-19),
12. 9034023 - Dynamic colorectal PDT application (2015-05-19),
13. 8999933 - Photodynamic cosmetic procedure and healing method (2015-04-07),
14. 8986731 - Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy (2015-03-24),
15. 8985121 - Method and device for valve repair (2015-03-24),
Company Overview
Biolitec Pharma Marketing Ltd is a specialized organization focused on the development and marketing of innovative medical technologies. The company is known for its expertise in laser-based therapies, particularly in the fields of urology, oncology, and vascular treatments. With a commitment to advancing healthcare solutions, Biolitec leverages cutting-edge research to enhance patient outcomes. Headquartered in Labuan, Malaysia, the company operates within a global context, aiming to provide effective and minimally invasive treatment options.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Biolitec Pharma Marketing Ltd USPTO Patent Assignee Logo
39 Patents

#1 in Labuan

#13 in Malaysia

#17,465 in the World

Labuan, MY
Labuan, Malaysia

Biolitec Pharma Marketing Ltd

Forward Citations = 130

51 inventors:

goldMedal Wolfgang Neuberger (24 out of 111 patents)

silverMedal Volker Albrecht (12 out of 21 patents)

bronzeMedal Susanna Gräfe (8 out of 9 patents)

4.  Arno Wiehe (6 out of 14 patents)

5.  Burkhard Gitter (5 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biolitec Pharma Marketing Ltd. Retrieved from https://idiyas.com/company/biolitec-pharma-marketing

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…